CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...
1don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...
CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to ...
UC and Broad have been involved in two interferences at the patent office. Interference No. 106,115 was the second interference between UC and Broad over patent rights to CRISPR-Cas9 technology in ...
A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback